Targeting triple-negative breast cancer: optimising therapeutic outcomes

Annals of Oncology, 05/04/2012

The use of biological preselection to guide therapy will improve therapeutic indices in target–bearing populations. Ongoing clinical trials of targeted agents in unselected triple–negative breast cancer (TNBC) populations have yet to produce substantial improvements in outcomes, and advancements will depend on their development in target–selected populations.

Print Article Summary Cat 2 CME Report